Inaphaea

Executive Summary

Inaphaea Biolabs is a translational CRO based in Cambridge, UK, specializing in custom cell-based assay development for oncology and women's health drug discovery. As a wholly-owned subsidiary of ValiRx plc, the company leverages a network of collaboration partners to offer integrated services from early research to pre-clinical development. Founded in 2021, Inaphaea aims to accelerate drug development by providing high-quality, reproducible assay data. While the company is still early-stage, its focus on niche areas and affiliation with ValiRx provide a foundation for growth. However, given its small size and limited public information, the near-term outlook is modest, with potential upside from strategic partnerships or expansion of service offerings.

Upcoming Catalysts (preview)

• Q3 2026Announcement of new strategic partnership with a major pharma company40% success
• Q4 2026Expansion of service offerings into immuno-oncology assays50% success
• Q2 2026ValiRx plc provides additional funding or reports positive progress from Inaphaea60% success